Switzerland's PolyPeptide H1 revenue rises on stronger metabolic therapeutics demand

PolyPeptide AG

13/08/2026 06:13

Overview
Switzerland peptide CDMO's H1 2026 revenue rose 42% yr/yr, driven by metabolic therapeutics
EBITDA margin improved to 20.7% from 2.7%, aided by higher sales and asset sale
Company raised 2026 revenue growth guidance to 25-30%, expects high-teens EBITDA margin

Outlook
PolyPeptide now expects 2026 revenue growth of 25-30% vs 2025 at constant currency rates
Company sees 2026 EBITDA margin in the high-teens, up from mid- to high-teens previously
PolyPeptide confirms mid-term target to double 2023 revenue by 2028

Result Drivers
METABOLIC THERAPEUTICS - Revenue growth was driven by strong demand for metabolic therapeutics, which rose 72.7% yr/yr
CAPACITY UTILIZATION - High utilization of new large-scale capacity in Belgium contributed to increased commercial revenue
LATE-STAGE CLINICAL DEMAND - Strong demand from late-stage clinical programs boosted development revenue

Company press release: ID:nEQ2BF4Nfa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 236.63 mln
 
H1 Net Income
 
EUR 9.08 mln
 
H1 Capex
 
EUR 41.32 mln
 
H1 Cash Flow from Operating Activities
 
EUR 25.22 mln
 
H1 EBIT
 
EUR 21.98 mln
 
H1 EBITDA
 
EUR 49.09 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for PolyPeptide Group AG is CHF40.00, about 9% below its August 12 closing price of CHF43.95
The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 51 three months ago

Reuters Recommended Reads
Aug 12 - Germany's Medios H1 profit hit by pricing pressure; to buy 74% of Caelo to expand API
Aug 12 - Sweden's Magle Chemoswed Q2 revenue rises on improved production efficiencies
Aug 10 - Bristol Myers to build $2.3 billion manufacturing site in Houston

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)